Bausch Health Companies Inc. (BHC): Price and Financial Metrics
Bausch Health Companies Inc. (BHC)
Today's Latest Price: $24.79 USD
Updated Jan 27 7:00pm
Add BHC to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
BHC Stock Summary
- Bausch Health Companies Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 97.79% of US listed stocks.
- BHC's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 99.26% of US stocks.
- Over the past twelve months, BHC has reported earnings growth of -155.52%, putting it ahead of merely 12.64% of US stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Bausch Health Companies Inc are ATLC, KFS, HCHC, SEAS, and COMM.
- BHC's SEC filings can be seen here. And to visit Bausch Health Companies Inc's official web site, go to www.bauschhealth.com.
BHC Stock Price Chart Interactive Chart >
BHC Price/Volume Stats
| Current price | $24.79 | 52-week high | $29.68 |
| Prev. close | $26.45 | 52-week low | $11.15 |
| Day low | $24.57 | Volume | 8,264,600 |
| Day high | $26.14 | Avg. volume | 4,840,612 |
| 50-day MA | $21.64 | Dividend yield | N/A |
| 200-day MA | $18.54 | Market Cap | 8.80B |
Bausch Health Companies Inc. (BHC) Company Bio
Bausch Health Cos. Inc. (formerly) Valeant Pharmaceuticals is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. The company was founded in 1983 and is based in Laval, Canada.
BHC Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $24.79 | $1.83 | -93% |
Below please find a table outlining a discounted cash flow forecast for BHC, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Bausch Health Companies Inc ranked in the 10th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for BHC, they are:
- In the past 5.52 years, Bausch Health Companies Inc has a compound free cash flow growth rate of -0.17%; that's better than just 8.96% of cash flow producing equities in the Healthcare sector, where it is classified.
- 28% of the company's capital comes from equity, which is greater than only 7.86% of stocks in our cash flow based forecasting set.
- Bausch Health Companies Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.3. This coverage rate is greater than that of only 24.31% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -93% |
| 1% | -93% |
| 2% | -93% |
| 3% | -93% |
| 4% | -93% |
| 5% | -93% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BHC, try EW, SRDX, COO, RHE, and OSMT.
Loading social stream, please wait...